We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
While the generic drug industry expressed support for recommendations in the Bush administration’s proposed fiscal 2008 budget that would speed up the approval process by collecting fees from manufacturers, the White House should focus on resolving key obstacles that impede bringing generic drugs to market, industry sources say.